Pharmaceuticals 11 February 2026 - 14 February 2026

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares rose 1.4% to $233.11 by early afternoon Tuesday, bucking a sharp drop in biotech ETFs. Investors traded on anticipation of management meetings and the pending $739 million XOMA Royalty acquisition. XOMA shares slipped 0.3%. The Ligand-XOMA deal still requires shareholder approval and could face delays.
June 2, 2026
AbbVie stock price climbs again after Botox lawsuit; what ABBV traders watch next
···

AbbVie stock price climbs again after Botox lawsuit; what ABBV traders watch next

AbbVie shares rose 1.8% to $231.50 in after-hours trading Friday following updates on its drug pipeline and ongoing litigation over Botox’s inclusion in Medicare price negotiations. Botox made up just over 10% of AbbVie’s $61.16 billion revenue last year. Investors are watching for mid-stage trial results in hidradenitis suppurativa and inflammatory bowel disease later this year. The next court update in the Botox case is expected Monday.
February 14, 2026
Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer
···

Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer

Merck shares closed down 0.03% at $119.28 after the FDA approved a Keytruda-based regimen for certain platinum-resistant ovarian cancer patients. The stock had reached $121.62 earlier in the session. Merck also announced new bladder and kidney cancer data to be presented at ASCO GU later this month. Chief Marketing Officer Chirfi Guindo sold 10,000 shares at an average price of $121.46.
February 12, 2026
Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus
···

Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus

Viking Therapeutics shares fell 0.7% to $28.55 in premarket trading Thursday after outlining plans to advance its oral obesity drug VK2735 into Phase 3 trials in the third quarter of 2026. The company completed enrollment for a Phase 3 injectable VK2735 study and reported a fourth-quarter net loss of $157.7 million, ending 2025 with $706 million in cash and equivalents.
February 12, 2026
1 2 3 4